7th Circuit Affirms Hormone Therapy Breast Cancer Claim Is Preempted
(October 19, 2016, 12:09 PM EDT) -- CHICAGO — The Seventh Circuit U.S. Court of Appeals on Oct. 18 affirmed judgment against a hormone replacement therapy plaintiff, finding that her claims are preempted by federal law and that she failed to timely assert her claim that generic manufacturer defendants failed to update their drug warning labels to warn of the risk of breast cancer (Kathleen A. Wagner v. Teva Pharmaceuticals USA, Inc., et al., No. 15-2294, 7th Cir.; 2016 U.S. App. LEXIS 18671).